CAR T Cell Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Phase 2
25
about 5.9 years
≤21
1 site in TN
About this study
This trial is testing a new treatment called CAR T cell therapy for people with leukemia that has returned or not responded to other treatments. The treatment involves modifying immune cells to fight cancer cells. Researchers are looking at different doses of chemotherapy drugs, how the body processes these drugs, and how long the CAR T cells last in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive CD19-CAR T cell Infusion
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cell therapy, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, mesna
infusion, oral (Oral Tablet)
Primary: Fludarabine Pharmacokinetics
Oncology